利用免疫治疗和新试验设计优化成人急性淋巴细胞白血病一线治疗:打破过去的传统
本文回顾了将伊诺妥珠单抗奥唑米星、贝林妥欧单抗等新型免疫治疗整合到初诊急性淋巴细胞白血病一线方案中的研究数据,指出这些方案正成为新的标准治疗。在费城染色体阳性急性淋巴细胞白血病中,贝林妥欧单抗联合BCR-ABL1酪氨酸激酶抑制剂的无化疗方案正在改变治疗格局。作者还讨论了随机研究在快速演变治疗格局中的挑战,并主张设计良好的非随机研究能更快推进标准治疗。
要点
- 伊诺妥珠单抗奥唑米星、贝林妥欧单抗及两种CD19 CAR-T产品均在美国获批用于复发或难治性B细胞急性淋巴细胞白血病的单药治疗。
- 将最有效疗法安全整合到一线方案可能最大程度发挥治愈潜力,而非仅用于挽救治疗。
- 费城染色体阳性急性淋巴细胞白血病中,贝林妥欧单抗联合BCR-ABL1酪氨酸激酶抑制剂的无化疗方案正在改变治疗。
核心结论
- 多种新型免疫治疗在初诊急性淋巴细胞白血病的一线整合研究已产生令人鼓舞的数据,这些方法正成为新的标准治疗。
- 在费城染色体阳性急性淋巴细胞白血病中,贝林妥欧单抗联合BCR-ABL1酪氨酸激酶抑制剂的无化疗方案正在改变治疗,凸显这些新药可能减少或消除某些亚型对化疗的需求。
- 作者认为设计良好的非随机研究能更快速推进急性淋巴细胞白血病的标准治疗。
研究设计与样本
- 本文为观点文章(Viewpoint),回顾正在进行的、探索初诊急性淋巴细胞白血病新型免疫治疗联合方案的临床试验数据。
主要发现
- 伊诺妥珠单抗奥唑米星、贝林妥欧单抗及两种CD19 CAR-T产品均在美国获批作为复发或难治性B细胞急性淋巴细胞白血病的单药治疗。
- 多项正在进行的初诊急性淋巴细胞白血病研究显示,常规整合伊诺妥珠单抗奥唑米星或贝林妥欧单抗或两者,已产生令人鼓舞的数据,这些方法正成为新的标准治疗。
- 在费城染色体阳性急性淋巴细胞白血病中,贝林妥欧单抗联合BCR-ABL1酪氨酸激酶抑制剂的无化疗方案正在改变治疗,凸显这些新药可能减少或消除某些亚型对化疗的需求。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multidrug chemotherapy has historically been the cornerstone of therapy for both children and adults with acute lymphocytic leukaemia. However, in the past decade, several novel immunotherapies have proven to be highly effective in the treatment of acute lymphocytic leukaemia, including the anti-CD22 antibody-drug conjugate inotuzumab ozogamicin, the CD3 × CD19 bispecific antibody blinatumomab, and two CD19-directed chimeric antigen receptor T-cell products. These agents are all approved in the USA as monotherapy for relapsed or refractory B-cell acute lymphocytic leukaemia. However, their use as single agents in the salvage setting might not be taking full advantage of their anti-leukaemia potential, because our ability to cure a patient is likely to be greatest when the most effective therapies are safety integrated into front-line treatment regimens. Several ongoing studies have yielded encouraging data with routine incorporation of inotuzumab ozogamicin or blinatumomab, or both, in patients with newly diagnosed acute lymphocytic leukaemia, and these approaches are emerging as new standards of care. In Philadelphia chromosome-positive acute lymphocytic leukaemia, chemotherapy-free regimens combining blinatumomab and a BCR-ABL1 tyrosine kinase inhibitor are changing acute lymphocytic leukaemia therapy, highlighting the potential for these novel agents to reduce-or perhaps eliminate-the need for chemotherapy in some subtypes. In this Viewpoint, we review promising data from ongoing clinical trials of novel immunotherapy-based combinations that are being explored in patients with newly diagnosed acute lymphocytic leukaemia. We also discuss the challenges of randomised studies in the rapidly evolving therapeutic landscape and argue for the ability of well designed, non-randomised studies to more rapidly advance the standard of care in acute lymphocytic leukaemia.
引用
- Short NJ, Kantarjian H. Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past. Lancet Haematol. 2023. PMID: 37003279. doi:10.1016/S2352-3026(23)00064-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。